Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
P/B ratio for Zealand Pharma A/S (ZEAL.CO)
P/B ratio as of 2023: 13.26
According to Zealand Pharma A/S's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 13.26. At the end of 2022 the company had a P/B ratio of 11.40.
P/B ratio history for Zealand Pharma A/S from 2007 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 13.26 |
| 2022 | 11.40 |
| 2021 | 6.70 |
| 2020 | 7.19 |
| 2019 | 6.40 |
| 2018 | 2.28 |
| 2017 | 4.67 |
| 2016 | 9.31 |
| 2015 | 13.85 |
| 2014 | 7.43 |
| 2013 | 4.22 |
| 2012 | 3.96 |
| 2011 | 2.88 |
| 2010 | 3.13 |
| 2009 | 11.44 |
| 2008 | 7.29 |
| 2007 | 6.27 |